Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Improving antihypertensive efficacy while maintaining placebo-like tolerability.

P S Sever1

  • 1Department of Clinical Pharmacology, Imperial College School of Medicine, St Mary's Hospital, London, UK.

Blood Pressure. Supplement
|November 4, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tissue Doppler echocardiography predicts long-term cardiovascular mortality: the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) legacy 20-year follow-up study.

Open heart·2025
Same author

ASCORE: an up-to-date cardiovascular risk score for hypertensive patients reflecting contemporary clinical practice developed using the (ASCOT-BPLA) trial data.

Journal of human hypertension·2013
Same author

Metabolic syndrome, impaired fasting glucose and obesity, as predictors of incident diabetes in 14 120 hypertensive patients of ASCOT-BPLA: comparison of their relative predictability using a novel approach.

Diabetic medicine : a journal of the British Diabetic Association·2011
Same author

How common is true resistant hypertension?

Journal of human hypertension·2010
Same author

The economic consequences of non-adherence to lipid-lowering therapy: results from the Anglo-Scandinavian-Cardiac Outcomes Trial.

International journal of clinical practice·2010
Same author

Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.

Heart (British Cardiac Society)·2007
Same journal

Efficacy and safety of early versus late titration of fixed-dose irbesartan/hydrochlorothiazide: ACTUAL study.

Blood pressure. Supplement·2012
Same journal

Efficacy and safety of valsartan in hypertensive Taiwanese patients: post-marketing surveillance study.

Blood pressure. Supplement·2012
Same journal

Effect of fixed dose combinations of metoprolol and amlodipine in essential hypertension: MARS--a randomized controlled trial.

Blood pressure. Supplement·2012
Same journal

Post-registration studies for the evaluation of antihypertensive drugs.

Blood pressure. Supplement·2012
Same journal

Effects of candesartan versus amlodipine on home-measured blood pressure, QT dispersion and left ventricular hypertrophy in high-risk hypertensive patients.

Blood pressure. Supplement·2011
Same journal

Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension.

Blood pressure. Supplement·2010
See all related articles

Candesartan cilexetil offers effective 24-hour blood pressure reduction with excellent tolerability, making it a significant advancement in antihypertensive therapies. It demonstrates superior efficacy compared to losartan and comparable results to irbesartan.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Choosing antihypertensive therapies involves considering potency, efficacy, duration, organ-specific effects, and tolerability.
  • Angiotensin II plays a key role in cardiovascular regulation, and its blockade is a primary therapeutic strategy.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of candesartan cilexetil as an antihypertensive agent.
  • To compare candesartan cilexetil with other antihypertensive drugs, including losartan and irbesartan.

Main Methods:

  • In vitro animal models were used to assess candesartan's binding to the angiotensin II type 1 (AT1) receptor.
  • Clinical trials compared the effects of candesartan cilexetil on blood pressure and the renin-angiotensin system against placebo, losartan, and irbesartan.

Related Experiment Videos

Main Results:

  • Candesartan cilexetil demonstrated potent, dose-dependent blood pressure reduction with placebo-like tolerability.
  • 16 mg of candesartan cilexetil was more effective than 50 mg of losartan in suppressing the renin-angiotensin system and reducing diastolic blood pressure.
  • Candesartan cilexetil showed equivalent efficacy to irbesartan and comparable blood pressure lowering to other major antihypertensive classes.

Conclusions:

  • Candesartan cilexetil provides sustained 24-hour blood pressure control.
  • Its unique binding characteristics and favorable tolerability profile position it as an important option in hypertension management.
  • Candesartan cilexetil is effective as monotherapy and in combination with other antihypertensives.